NCT04829604 2026-03-09ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Ambrx, Inc.Phase 2 Active not recruiting72 enrolled
NCT05041972 2022-09-13ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)Ambrx, Inc.Phase 2 Withdrawn